The psychedelic drug market is projected to develop at a compound annual progress fee of 16.3% over the subsequent eight years to succeed in $6.85 billion by 2026, based on Data Bridge Market Research. With the potential to deal with a variety of psychological well being issues, a number of organizations are already conducting medical trials in the house.
Let’s check out MagicMed’s Psybrary™, the present stage of improvement and the way it might revolutionize psychedelic drug discovery.
What is the Psybrary™?
MagicMed’s Psybrary™ is a portfolio of psychedelic molecules and the patents that shield them. While the firm is targeted on psychedelic drug discovery, the aim is to license these molecules to biotech or pharmaceutical corporations for medical improvement (the place it should earn milestone funds), and finally, commercialization (the place it should earn royalties).
MagicMed CEO Dr. Joseph Tucker explains its proprietary Psybrary™
The firm combines artificial biology—or taking enzymes from nature and utilizing them to make modifications to molecules—with traditional chemistry to create hundreds of novel psychedelic molecules. These molecules are protected by each composition of matter and methodology of producing patents to construct a strong and defensible portfolio.
With years of expertise in creating modern manufacturing strategies for plant-derived prescription drugs, the firm has constructed a powerful basis of novel molecules primarily based on psilocybin and ayahuasca. Management is able to work with business companions to commercialize these molecules whereas pursuing new molecules primarily based on MDMA, ketamine, ibogaine and different sorts of psychedelic molecules over the subsequent 12 months.
A Unique Business Model
MagicMed’s administration staff is targeted on psychedelic drug discovery—the first a part of the drug improvement course of. With expertise in creating opiates, cannabinoids and ephedra derivatives, the firm is uniquely positioned to leverage its a long time of expertise and proprietary strategies in the psychedelic business.
CEO Dr. Joseph Tucker mentioned current and future alternatives for enterprise companions
Dr. Peter Facchini has revealed greater than 160 scientific papers and holds 20 patents in the molecular derivatives discipline. Meanwhile, Dr. Jillian Hagel has held COO and VP roles throughout the biotech business the place she was instrumental in constructing patent portfolios and coordinating partnerships to drive important long-term worth for shareholders.
The firm’s enterprise mannequin is exclusive as a result of, as soon as it develops a brand new molecule—which it’s doing for hundreds of molecules—there’s little extra capital prices. By licensing the molecule, the firm shifts the threat of improvement and commercialization to a different enterprise whereas retaining milestone funds and potential royalties on gross sales.
MagicMed Industries is uniquely positioned to capitalize on the rising demand for psychedelic therapies for varied psychological diseases. With its modern enterprise mannequin, shareholders may benefit from a various vary of high-margin recurring income streams.
The firm hopes to onboard its first associate this 12 months whereas concentrating on a public itemizing throughout the first or second quarter of subsequent 12 months when it achieves a optimistic money movement. In 2022, administration hopes to start out receiving milestone funds and doubtlessly diversify into the massive and rising licit client items business.
The above article is sponsored content material. CannabisFN.com and CFN Media, have been employed to create consciousness. Please comply with the hyperlink beneath to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/
This article was revealed by CFN Enterprises Inc. (OTCQB: CNFN), proprietor and operator of CFN Media, the business’s main company and digital monetary media community devoted to the burgeoning CBD and authorized hashish industries. Call +1 (833) 420-CNFN for extra info.